BRAF mutations in hairy-cell leukemia

Enrico Tiacci, Vladimir Trifonov, Gianluca Schiavoni, Antony Holmes, Wolfgang Kern, Maria Paola Martelli, Alessandra Pucciarini, Barbara Bigerna, Roberta Pacini, Victoria A. Wells, Paolo Sportoletti, Valentina Pettirossi, Roberta Mannucci, Oliver Elliott, Arcangelo Liso, Achille Ambrosetti, Alessandro Pulsoni, Francesco Forconi, Livio Trentin, Gianpietro SemenzatoGiorgio Inghirami, Monia Capponi, Francesco Di Raimondo, Caterina Patti, Luca Arcaini, Pellegrino Musto, Stefano Pileri, Claudia Haferlach, Susanne Schnittger, Giovanni Pizzolo, Robin Foà, Laurent Farinelli, Torsten Haferlach, Laura Pasqualucci, Raul Rabadan, Brunangelo Falini

Research output: Contribution to journalArticle

623 Citations (Scopus)

Abstract

Background: Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. Methods: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. Results: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. Conclusions: The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)

Original languageEnglish
Pages (from-to)2305-2315
Number of pages11
JournalNew England Journal of Medicine
Volume364
Issue number24
DOIs
Publication statusPublished - Jun 16 2011

Fingerprint

Hairy Cell Leukemia
Mutation
Mitogen-Activated Protein Kinase Kinases
Exome
Lymphoma
Proto-Oncogene Proteins B-raf
B-Cell Leukemia
High-Throughput Nucleotide Sequencing
B-Cell Lymphoma
Mitogen-Activated Protein Kinases
Leukemia
Western Blotting

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M. P., ... Falini, B. (2011). BRAF mutations in hairy-cell leukemia. New England Journal of Medicine, 364(24), 2305-2315. https://doi.org/10.1056/NEJMoa1014209

BRAF mutations in hairy-cell leukemia. / Tiacci, Enrico; Trifonov, Vladimir; Schiavoni, Gianluca; Holmes, Antony; Kern, Wolfgang; Martelli, Maria Paola; Pucciarini, Alessandra; Bigerna, Barbara; Pacini, Roberta; Wells, Victoria A.; Sportoletti, Paolo; Pettirossi, Valentina; Mannucci, Roberta; Elliott, Oliver; Liso, Arcangelo; Ambrosetti, Achille; Pulsoni, Alessandro; Forconi, Francesco; Trentin, Livio; Semenzato, Gianpietro; Inghirami, Giorgio; Capponi, Monia; Di Raimondo, Francesco; Patti, Caterina; Arcaini, Luca; Musto, Pellegrino; Pileri, Stefano; Haferlach, Claudia; Schnittger, Susanne; Pizzolo, Giovanni; Foà, Robin; Farinelli, Laurent; Haferlach, Torsten; Pasqualucci, Laura; Rabadan, Raul; Falini, Brunangelo.

In: New England Journal of Medicine, Vol. 364, No. 24, 16.06.2011, p. 2305-2315.

Research output: Contribution to journalArticle

Tiacci, E, Trifonov, V, Schiavoni, G, Holmes, A, Kern, W, Martelli, MP, Pucciarini, A, Bigerna, B, Pacini, R, Wells, VA, Sportoletti, P, Pettirossi, V, Mannucci, R, Elliott, O, Liso, A, Ambrosetti, A, Pulsoni, A, Forconi, F, Trentin, L, Semenzato, G, Inghirami, G, Capponi, M, Di Raimondo, F, Patti, C, Arcaini, L, Musto, P, Pileri, S, Haferlach, C, Schnittger, S, Pizzolo, G, Foà, R, Farinelli, L, Haferlach, T, Pasqualucci, L, Rabadan, R & Falini, B 2011, 'BRAF mutations in hairy-cell leukemia', New England Journal of Medicine, vol. 364, no. 24, pp. 2305-2315. https://doi.org/10.1056/NEJMoa1014209
Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP et al. BRAF mutations in hairy-cell leukemia. New England Journal of Medicine. 2011 Jun 16;364(24):2305-2315. https://doi.org/10.1056/NEJMoa1014209
Tiacci, Enrico ; Trifonov, Vladimir ; Schiavoni, Gianluca ; Holmes, Antony ; Kern, Wolfgang ; Martelli, Maria Paola ; Pucciarini, Alessandra ; Bigerna, Barbara ; Pacini, Roberta ; Wells, Victoria A. ; Sportoletti, Paolo ; Pettirossi, Valentina ; Mannucci, Roberta ; Elliott, Oliver ; Liso, Arcangelo ; Ambrosetti, Achille ; Pulsoni, Alessandro ; Forconi, Francesco ; Trentin, Livio ; Semenzato, Gianpietro ; Inghirami, Giorgio ; Capponi, Monia ; Di Raimondo, Francesco ; Patti, Caterina ; Arcaini, Luca ; Musto, Pellegrino ; Pileri, Stefano ; Haferlach, Claudia ; Schnittger, Susanne ; Pizzolo, Giovanni ; Foà, Robin ; Farinelli, Laurent ; Haferlach, Torsten ; Pasqualucci, Laura ; Rabadan, Raul ; Falini, Brunangelo. / BRAF mutations in hairy-cell leukemia. In: New England Journal of Medicine. 2011 ; Vol. 364, No. 24. pp. 2305-2315.
@article{7b5d4a268a414d93bc5f2be2ce545a76,
title = "BRAF mutations in hairy-cell leukemia",
abstract = "Background: Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. Methods: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. Results: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. Conclusions: The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)",
author = "Enrico Tiacci and Vladimir Trifonov and Gianluca Schiavoni and Antony Holmes and Wolfgang Kern and Martelli, {Maria Paola} and Alessandra Pucciarini and Barbara Bigerna and Roberta Pacini and Wells, {Victoria A.} and Paolo Sportoletti and Valentina Pettirossi and Roberta Mannucci and Oliver Elliott and Arcangelo Liso and Achille Ambrosetti and Alessandro Pulsoni and Francesco Forconi and Livio Trentin and Gianpietro Semenzato and Giorgio Inghirami and Monia Capponi and {Di Raimondo}, Francesco and Caterina Patti and Luca Arcaini and Pellegrino Musto and Stefano Pileri and Claudia Haferlach and Susanne Schnittger and Giovanni Pizzolo and Robin Fo{\`a} and Laurent Farinelli and Torsten Haferlach and Laura Pasqualucci and Raul Rabadan and Brunangelo Falini",
year = "2011",
month = "6",
day = "16",
doi = "10.1056/NEJMoa1014209",
language = "English",
volume = "364",
pages = "2305--2315",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "24",

}

TY - JOUR

T1 - BRAF mutations in hairy-cell leukemia

AU - Tiacci, Enrico

AU - Trifonov, Vladimir

AU - Schiavoni, Gianluca

AU - Holmes, Antony

AU - Kern, Wolfgang

AU - Martelli, Maria Paola

AU - Pucciarini, Alessandra

AU - Bigerna, Barbara

AU - Pacini, Roberta

AU - Wells, Victoria A.

AU - Sportoletti, Paolo

AU - Pettirossi, Valentina

AU - Mannucci, Roberta

AU - Elliott, Oliver

AU - Liso, Arcangelo

AU - Ambrosetti, Achille

AU - Pulsoni, Alessandro

AU - Forconi, Francesco

AU - Trentin, Livio

AU - Semenzato, Gianpietro

AU - Inghirami, Giorgio

AU - Capponi, Monia

AU - Di Raimondo, Francesco

AU - Patti, Caterina

AU - Arcaini, Luca

AU - Musto, Pellegrino

AU - Pileri, Stefano

AU - Haferlach, Claudia

AU - Schnittger, Susanne

AU - Pizzolo, Giovanni

AU - Foà, Robin

AU - Farinelli, Laurent

AU - Haferlach, Torsten

AU - Pasqualucci, Laura

AU - Rabadan, Raul

AU - Falini, Brunangelo

PY - 2011/6/16

Y1 - 2011/6/16

N2 - Background: Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. Methods: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. Results: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. Conclusions: The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)

AB - Background: Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. Methods: We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. Results: Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF-MEK-ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. Conclusions: The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)

UR - http://www.scopus.com/inward/record.url?scp=79959293462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959293462&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa1014209

DO - 10.1056/NEJMoa1014209

M3 - Article

C2 - 21663470

AN - SCOPUS:79959293462

VL - 364

SP - 2305

EP - 2315

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 24

ER -